Key result
A previous report concluded that sulfinpyrazone reduced cardiac mortality by 32% and sudden death by 43% compared with placebo after myocardial infarction.
Why the study?
Does sulfinpyrazone reduce cardiac mortality and sudden death in patients after myocardial infarction?
Does sulfinpyrazone reduce cardiac mortality and sudden death in patients after myocardial infarction?
Effect estimate: 32% reduction in cardiac mortality; 43% reduction in sudden death
This editorial discusses the preliminary and follow-up reports on sulfinpyrazone for preventing sudden death post-myocardial infarction, noting the need for further decision-making.
In February 1978, the Journal published a preliminary report of the successful use of sulfinpyrazone (Anturane) in the prevention of sudden death after myocardial infarction.1 A second report, based on a longer period of treatment, appeared in January of this year2 and concluded that the drug reduced cardiac mortality by 32 per cent and sudden death by 43 per cent, as compared with a placebo. This seemingly dramatic and encouraging development was made all the more so by contrast with the disappointing results of a large-scale trial of aspirin that appeared at about the same time.3 Although sulfinpyrazone has antiplatelet . . .
No takes yet. Share an insight, caveat, or question.
Arnold S. Relman (1980) conducted an editorial in Myocardial Infarction. Sulfinpyrazone vs. Placebo was evaluated on Cardiac mortality and sudden death (32% reduction in cardiac mortality; 43% reduction in sudden death). A previous report concluded that sulfinpyrazone reduced cardiac mortality by 32% and sudden death by 43% compared with placebo after myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: